



Healthia

Better Health. Better Lives.



**Investor Presentation
Financial Year ended 30 June 2021**

Healthia Limited
ACN 626 087 223

Contents


-
1. FY21 Highlights
 2. FY21 Financial Performance
 3. FY22 Outlook
-

Appendices

- A. Business Overview
 - B. Other Financial Information
-



1. FY21 Highlights



Key Highlights

Underlying Revenue¹



\$140.4m

+52% vs PCP
9.1% organic growth²

Underlying EBITDA³



\$21.5m

+62% vs PCP

Underlying NPATA⁴ (attributable to owners)



\$8.9m

+91% vs PCP

Underlying EPS⁵



11.13cps

+52% vs PCP

Capital deployed



\$62.3m

Target +\$20m p.a.

FY21 dividends



4.5cps

2.5cps final dividend

Clinics



212

+61 clinics vs PCP
As at 30 June 2021

Finance Facility



+\$20.0m

Increased from \$50m
to \$70m

Clinicians



723

+155 (or +27%) clinicians
vs PCP

1 For the purposes of underlying results, the Consolidated Entity has excluded \$5.61M (of \$7.61M total) JobKeeper revenue subsidies from underlying results. The remaining \$1.99M is the Directors assessment of the impact on trading from lockdowns. Underlying revenue has not been audited.

2 Organic revenue growth has been calculated by excluding any closed businesses and businesses not held during the prior corresponding period. Organic revenue growth has been adjusted to remove the impact of COVID related lockdowns in the current and prior financial years. Organic revenue growth has not been presented for the acquired Eyes & Ears Division as the Consolidated Entity did not hold the Eyes & Ears businesses for a whole 12 months.

3 Underlying EBITDA is a non-IFRS measure and equals earnings before interest, tax, depreciation and amortisation. Underlying EBITDA has been adjusted to remove the impact of AASB16. Underlying EBITDA has not been audited.

4 Underlying NPATA is a non-IFRS measure and equals net profit after income tax expense plus amortisation of customer list intangibles. Underlying NPATA has not been audited.

5 Underlying basic EPS or earning per share is calculated as NPATA attributable to the owners of Healthia Limited divided by weighted average number of ordinary shares on issue (FY21:79.63M, FY20: 63.04M). Underlying basic EPS has not been audited

Operational Highlights

GROWTH



- Organic growth of 9.1%¹
- Acquisition of The Optical Company, representing 41 optical stores and eyewear frame distributor, AED
- Acquisition of additional 19 allied health businesses (11 Bodies and Minds businesses, 7 Feet and Ankles businesses and 1 additional Eyes and Ears business)
- Launch of audiology services inside an existing Healthia owned optometry clinic in Geelong
- Opening of a new greenfield allied health clinic in Bundaberg (profitable in first month of operation)

RECRUITMENT & RETENTION



- Team engagement continues to strengthen, with a recent people survey returning an engagement score of 62%² categorising Healthia as a 'Culture of Success'
- Clinician staff retention rate remained high at 85% (FY20: 85%)
- Recruitment of 60 new graduate health professionals during FY21
- Clinic Class Share ownership grew to a total of 2,984 Clinic Class Shares on issue, up from 2,505 in FY20

EDUCATION & DEVELOPMENT



Continued development of Healthia's industry leading education platforms and programs. The follow programs are now offered to Healthia's team members:


- Graduate training program
- Clinical Leadership Program
- Business Leadership Program
- Practice Management Program
- Biennial conference

OPERATIONAL EFFICIENCY



- Integration of The Optical Company, including incorporation in the Clinician Retention Program, alignment of marketing strategies and customer retention programs and consolidation of the acquired entities to improve accounting/support efficiencies
- Recruitment of Healthia's Chief Marketing Officer and refinement of the digital marketing strategy

2. FY21 Financial Performance



Underlying Performance

Healthia Limited – Underlying FY21 performance compared to Underlying FY20 performance

This table has not been audited

| | 30/06/2021 \$'000's <i>Underlying</i> ² | 30/06/2020 \$'000's <i>Underlying</i> ² | Change \$ | Change % |
|--|--|--|--------------|--------------|
| Underlying Revenue ¹ | 140,407 | 92,493 | 47,914 | 51.8% |
| Underlying EBITDA ^{3,4} (removing impact of AASB16) | 21,468 | 13,230 | 8,238 | 62.3% |
| Underlying net profit before income tax expense | 15,080 | 9,239 | 5,841 | 63.2% |
| Underlying net profit after income tax expense | 10,251 | 5,806 | 4,445 | 76.6% |
| Amortisation expense | 1,017 | 661 | 356 | 53.8% |
| Underlying NPATA ⁵ | 11,268 | 6,467 | 4,801 | 74.2% |
| Non-controlling interest (NCI) | 2,995 | 2,041 | 954 | 46.7% |
| Net post-tax P&L impact of AASB16 adoption ⁶ | 588 | 203 | 385 | 189.6% |
| Underlying NPATA attributable to the owners of Healthia Limited (removing impact of AASB16)⁵ | 8,861 | 4,629 | 4,232 | 91.4% |
| Underlying EBITDA margin (removing impact of AASB16) ^{3,4} | 15.29% | 14.30% | 0.99% | 99 bps |
| Underlying NPATA margin (removing impact AASB16) ⁵ | 6.31% | 5.00% | 1.31% | 131 bps |
| Underlying Basic EPS (cents, removing impact AASB16) ⁷ | 11.13 | 7.34 | 3.79 | 51.6% |
| NCI / Underlying NPATA ⁸ | 26.58% | 31.56% | -4.98% | -498 bps |

1. For the purposes of underlying results, the Consolidated Entity has excluded \$5.61M (of \$7.61M total) JobKeeper revenue subsidies from underlying results. The remaining \$1.99M is the Directors assessment of the impact on trading from lockdowns.

2. Underlying profit reflects statutory profit as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance with AICD/Finsia principles of recording underlying profit. Underlying profit has not been audited

3. Underlying EBITDA is a non-IFRS measure and equals earnings before interest, tax, depreciation and amortisation.

4. Underlying EBITDA has been adjusted for the impacts of AASB16. Lease payments of \$11.48m have been included to provide users with a like-for-like comparison with PCP.

5. Underlying NPATA is a non-IFRS measure and equals net profit after income tax expense plus amortisation of customer list intangibles.

6. The net post-tax P&L impact of the new leasing standard, AASB16, has been added back to NPATA to provide users with a like-for-like comparison with PCP. The pre-tax impact of AASB 16 'Leases' in the current period is comprised of the following: occupancy costs decreased by \$11.48M, depreciation expense increased by \$10.31M, and finance costs increased by \$2.01M.

7. Underlying EPS or earnings per share is calculated as Underlying NPATA attributable to the owners of Healthia Limited divided by the weighted average number of ordinary shares on issue for the period (FY21: 79.63M, FY20: 63.04M).

8. Non-Controlling Interest divided by Underlying NPATA.

Strong underlying growth during the financial year attributable to:


- Organic revenue growth of 9.1% achieved;
- The deployment of \$62.3m of capital on new clinic acquisitions during the period;
- the resilient and essential nature of the allied health services provided;
- organic growth initiatives such as targeted marketing and patient/ customer attraction, conversion, retention strategies, structured education and professional development strategies and the introduction of additional services into existing clinics;
- strong cultural engagement and clinician retention rates

Fully franked final dividend of 2.5 cents per share.


A reconciliation from Underlying to Statutory Performance is detailed in slide 25.

Healthia is delivering a strong growth trajectory


Revenue




Underlying EBITDA^{1,2}



Underlying NPATA^{1,3} (attributable to owners)



Businesses owned⁴



1 Underlying profit reflects statutory profit as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance with AICD/Finsia principles of recording underlying profit. Underlying profit has not been audited or reviewed.
2 EBITDA means Earnings Before Interest Tax Depreciation and Amortization, and removes impact of AASB16

3 NPATA means net profit after tax plus amortization
4 F&A refers to the Feet and Ankles division. B&M refers to the Bodies and Minds division. E&E refers to the Eyes and Ears division.

Healthia has delivered strong and consistent cash flow conversion

Underlying cash flow conversion for period ended 30 June 2021

This table has not been audited

| | 30/06/2021 | 30/06/2020 |
|--|------------|------------|
| | \$'000's | \$'000's |
| Underlying EBITDA ¹ (removing impact of AASB16) | 21,468 | 13,230 |
| Changes in working capital | 3,381 | (1,831) |
| Underlying Operating Cash Flows (pre-tax, ungeared) ² | 18,087 | 15,061 |
| Conversion (%) | 84.2% | 113.8% |

1. Underlying EBITDA reflects statutory EBITDA as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the Consolidated Entity, in accordance with AICD/Finsia principles. Underlying EBITDA excludes the impact from the adoption of AASB16 on lease payments of \$11.48M

2. Underlying operating cash flows (pre-tax, ungeared) reflects statutory operating cash flows less lease payments and before finance costs and tax and excludes the impact non-recurring income and costs, such as acquisition and integration costs (\$4.21M)

COVID-19 Lockdowns

Impact of Lockdowns during H2 2021

| | <i>Clinic days impacted by lockdowns ¹ 1/1/21 - 30/6/21</i> | <i>Total clinic trading days ² 1/1/21 - 30/6/21</i> | <i>%</i> |
|--------------|--|--|-------------|
| VIC | 581 | 5,698 | 10.2% |
| NSW | 250 | 5,513 | 4.5% |
| QLD | 661 | 16,207 | 4.1% |
| NT | 6 | 296 | 2.0% |
| WA | 35 | 740 | 4.7% |
| TAS | | 444 | 0.0% |
| SA | | 1,961 | 0.0% |
| Total | 1,533 | 30,859 | 5.0% |

Notes


1. Calculated as working days impacted by COVID-19 related lockdowns multiplied by the number of clinics owned by the Consolidated Entity (for each respective lockdown).

2. Calculated as working days multiplied by the number of clinics owned by the Consolidated Entity; adjusted for the impact of acquisitions during the period.

During the second half of FY2021, as a result of increasing COVID-19 cases, an increasing number of lockdown restrictions were imposed in key regions of Australia, including Sydney, Melbourne, Brisbane, Perth and Darwin.

Healthia estimates that lockdowns impacted over 1,533 clinic trading days, representing approximately 5.0% of total clinic trading days. Healthia, as a provider of a number of essential community health care services, continued providing these essential services from its allied health clinics with strong infection control protocols in place.


The impacts of lockdowns from COVID-19 are unpredictable given that the timing of, and length of time in, lockdowns vary. However, the experience of prior lockdowns has shown that any short-term reduction in patient volumes is quickly recovered with the pent-up demand typically experienced after such restrictions ease or end.



Business Portfolio

Healthia owns and operates Australia's largest and fastest growing allied health portfolio


Businesses Owned as at 30/06/2021



Businesses Owned as at 30/06/2021

| | Feet & Ankles | Bodies & Minds | Eyes & Ears | Total | % |
|--------------------------|---------------|----------------|-------------|------------|---------------|
| | Businesses | Businesses | Businesses | Businesses | |
| Queensland | 45 | 55 | 15 | 115 | 54.2% |
| New South Wales & ACT | 15 | 6 | 14 | 35 | 16.5% |
| Victoria | 24 | 2 | 12 | 38 | 17.9% |
| Tasmania | 2 | 0 | 0 | 2 | 0.9% |
| South Australia | 9 | 3 | 2 | 14 | 6.6% |
| Western Australia | 5 | 0 | 0 | 5 | 2.4% |
| Northern Territory | 2 | 0 | 0 | 2 | 0.9% |
| United States of America | 1 | 0 | 0 | 1 | 0.5% |
| Total Businesses | 103 | 66 | 43 | 212 | 100.0% |
| % of Total | 49% | 31% | 20% | 100% | |

Geographic Split of Businesses Owned from 30/06/2019 to 30/06/2021




Organic growth

Organic growth continues to accelerate as a result of the focus and investment in industry leading education, tools and support for our clinicians and team members



Experienced Team

- Businesses led by founding clinicians
- Founding clinicians supported by experienced board and senior management team
- Board and Senior Management team have over 100 years of collective experience in running multi-location health practices



Systems & Support

- Patient focused
- Clinician Retention Program
- Clinician Education Programs
- Clinical Advisory Committees
- Centralised support including benchmarking and coaching
- Centralised web based practice software systems (Nookal & Optomate)
- Targeted marketing and patient retention strategies
- Cross referrals and patient engagement strategies



Education

Established industry leading education programs, including:

1. Recent Graduate Program;
2. Clinic Leadership Program;
3. Business Leadership Program;
4. Practice Management Program;
5. Biennial conference.

- Programs intended to support clinicians working within clinics, from new graduates to experienced staff members





Clinician Business Ownership


- Career path for all staff which includes steps from joining the group as a graduate clinician and working through to equity ownership
- Clinician business ownership model allows for clinician ownership in the clinic, via Clinic Class Shares
- Provides stability, and allows for a more streamlined succession plan for, for key clinicians

Addressable Market


FEET & ANKLES




BODIES & MINDS



EYES & EARS



TOTAL ADDRESSABLE REVENUE



HEALTHIA MARKET SHARE OF INDUSTRY REVENUE

Compelling addressable market opportunity with less than 1.5% current market share.

The acquisition of The Optical Company has:

- Increased Healthia's addressable industry market from \$6.5b to \$9.8b (+51%)
- Delivered a scalable, vertically integrated platform to grow in the optical and audiology industries

Notes: (1) Australian Podiatry Industry Revenue of \$864m (Source: IBISWorld Industry Report Q8539 dated December 2016) + Insole United States Industry Revenue of \$1.8bn (Source: Transparency Market Research, "Foot Orthotic Insoles Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026"). (2) Australian Physiotherapy Industry Revenue of \$2.5bn (Source: IBISWorld Industry Report Q8533 dated September 2020) + Other Allied Health Services in Australia Industry Revenue of \$1.3bn (Source: IBISWorld AU Industry (ANZSIC) Report Q8533 dated September 2020) (3) Australian Optometry Industry Revenue of \$2.2bn which is equal to the industry revenue of \$3.8bn less the market share held by Luxottica and Specsavers (Source: IBISWorld Industry Report Q8532 dated February 2020) + Audiology AUD Industry Revenue of \$1.1bn (Source: IBISWorld Industry Report Q8539 dated December 2016) (4) Total addressable revenue has only been included for industries where information was available or reliable. Addressable industries revenue excludes address industry revenue from Australian insole market, Australian allied health wholesale supplies, Australian optical eyewear supplies and Australian retail footwear.

Acquisitions

Healthia deployed capital of \$62.3m in FY21 at an effective EBITDA multiple of 6.9x

Summary of acquisitions settled between 1 July 2020 and 30 June 2021


| <u>Annualised FY21 Underlying Performance</u> | | | <u>Consideration</u> | <u>Multiple</u> | |
|---|--|---|----------------------------|--|---|
| Revenue | EBITDA^{1,2} (before group support costs) | EBITDA^{1,2} (after group support costs) | Total Consideration | EBITDA^{1,2} Multiple* (before group support costs) | EBITDA^{1,2} Multiple* (after group support costs) |
| \$'000's | \$'000's | \$'000's | \$'000's | \$'000's | \$'000's |
| 54,135 | 11,834 | 8,988 | 62,336 | 5.3x | 6.9x |

1. Underlying profit reflects statutory profit as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the consolidated entity, in accordance with AICD/Finsia principles of recording underlying profit. Underlying profit has not been audited or reviewed
2. Underlying EBITDA excludes the impact from the adoption of AASB16 on lease payments.

Acquisitions completed in FY21 have delivered to expectations.

In addition to acquisitions completed during FY21, Healthia has also announced the subsequent acquisitions of 3 optometry clinics and 2 physiotherapy clinics. The acquisitions are expected to contribute additional pro-forma revenue and EBITDA of \$3.95m and \$0.64m.

3. FY22 Outlook







Outlook

- Healthia will continue to focus on its **4-tiered strategy** being:
 1. patient focused outcomes;
 2. organic growth;
 3. future accretive acquisitions; and
 4. vertically integrated business units.
- Healthia will focus on continuing to build on the momentum created from organic growth activities, including further enhancing the centralized support to clinical teams, finding additional opportunities to co-locate services and introduce new services into existing locations, and work on new ways to continue to engage its teams.
- With an addressable market in excess of \$9.8b, Healthia is confident of deploying the stated target of **\$20.0m of capital** for the acquisition of new allied health businesses over the next 12 months,. Healthia has a range of funding sources which can be utilized to fund this acquisition growth, including headroom in Healthia's finance facility (\$21.67M at 30 June 2021) , operating cash flow and Clinic Class Shares.
- The Directors will continue to manage and monitor the impacts from COVID lockdowns. The experience of prior lockdowns has shown that any short-term reduction in patient volumes is quickly recovered with the pent-up demand typically experienced after lockdown restrictions end.

Appendices




A. Business Overview



ALLSPORTS
Physiotherapy

MyFootDr.
Podiatry



Vision & Structure

Healthia's vision is to be Australia's leading diversified healthcare provider



Vertical Integration

Healthia's operates a vertically integrated business model. Each of the businesses are scalable and provide significant benefits and cost savings from newly acquired clinics.


| Brand | Description |
|---|--|
|  | <ul style="list-style-type: none">• TOC owns and operates an established eyewear frame distributor, Australian Eyewear Distributors (AED), providing a vertically integrated model• AED distributes a diverse range of premium, fashionable eyewear products consisting of both international and private label brands to the TOC Group |
|  | <ul style="list-style-type: none">• Produces foam rubber EVA and 3D printed orthotic devices, using computer software and hardware.• Established systems to produce 3D printed orthotics which are sustainable, cost effective and of a high quality• Currently 3D printing orthotics for the North American market |
|  | <ul style="list-style-type: none">• Podiatry and foot care for podiatrists, hospitals, medical centres, nursing homes and allied health professionals in all Australian States and New Zealand |

AED Private Label Examples:



History of Healthia

Group of established & reputable allied health clinics which have operated over a long period of time



Board of Directors

Experienced board members with deep industry expertise in each of Healthia's key operating segments



GLEN RICHARDS

Non-Executive Chair

Dr Richards has over 29 years of experience in the retail and professional services sectors with extensive operational experience in fast growing companies, especially in health care and allied health sectors. Dr Richards was the founding Managing Director of Greencross Limited and Co-Founder of Mammoth Pet Holdings Pty Ltd, prior to its merger with Greencross Limited in 2014. Glen is currently Chairman of People Infrastructure Ltd, Naturo Technologies and Cardionexus Pty Ltd. Non executive director of Adventure Holdings Pty Ltd and De Motu Cordis Pty Ltd.



PAUL WILSON

Non-Executive Director

Paul was a co-founder, director and shareholder of Mammoth Pet Holdings Pty Ltd (Pet Barn) prior to the merger with Greencross Limited.

Prior to founding Mammoth, Paul was the Chief Operating Officer of ShopFast, Australia's largest online grocery retailer (sold to Coles in 2003).

Paul has worked in the retail industry for 26 years with roles including, General Manager of Caltex/Boral JV, Vitalgas.



LISA DALTON

Non-Executive Director

Lisa is an experienced director, senior executive and company secretary with expertise in the healthcare, medical, utilities, manufacturing, childcare, energy, mining and construction sectors.

Lisa has experience in leading teams responsible for strategy, governance, risk management, human resources, communication, stakeholder relations and program management.



WES COOTE

Group Managing Director & Group CEO

Wesley is the former Chief Financial Officer and Company Secretary of Greencross Ltd. Prior to Greencross, Wesley worked in Chartered Accounting where he provided businesses advice within the health sector, property sector and financial services industry.

Wesley holds a Bachelor of Commerce from the University of Queensland and is a member of the Institute of Chartered Accountants, as well as a member of the Governance Institute of Australia.



TONY GANTER

Chief Business Development & Strategy Officer

Tony has over 28 years' experience in the management and operation of private physiotherapy and sports medicine clinics and high-performance medical teams in professional sport. He possesses knowledge of the professional, administrative and management skills required to operate physiotherapy and sports medicine centres.

Tony remains active as a treating physiotherapist which enables him to keep in touch with the challenges of both professional health care and clinic ownership.



DARREN STEWART

Executive Director

Darren is a registered podiatrist and in 2004 co-founded the My FootDr Business with Greg Dower. The two had grown the group to 13 clinics by December 2015.

In 2015, Darren and Greg saw the opportunity to grow their network of Clinics through the acquisition of well-established podiatry clinics. Before merging with Balance Podiatry Group in December 2016, they had grown the network to 19 clinics.

Darren provides strategic leadership and direction to the Feet & Ankles division.




COLIN KANGISSER

CEO – Eyes & Ears Division & Director

Colin is a registered optometrist with over 30 years' optical experience. He founded, grew and exited multiple retail chains including Optic Express and Kays Optical prior to holding executive leadership positions with the OPSM Group and founding TOC in 2005. Colin will continue as CEO of the Eyes & Ears division and become a Director of Healthia Limited post completion.

B. Other Financial Information



Statutory Results

Healthia Limited - Statutory Financial Performance

| | 30/06/2021 \$'000's | 30/06/2020 \$'000's | Change \$'000's | Change % |
|--|------------------------|------------------------|--------------------|--------------|
| Revenue and Other Income | 146,026 | 96,366 | 49,660 | 51.5% |
| Net profit before income tax expense | 13,150 | 7,253 | 5,897 | 81.3% |
| Net profit after income tax expense | 9,177 | 5,148 | 4,029 | 78.3% |
| Non-controlling interest (NCI) | 4,020 | 2,457 | 1,563 | 63.6% |
| NPAT attributable to the owners of Healthia Limited¹ | 5,157 | 2,691 | 2,466 | 91.6% |

1. Net profit after income tax expense, net of Non-Controlling Interest (NCI)

Total income for the period (Revenue plus Other Income), increased by \$49.66m or 51.5%

Both periods have been affected by significant non-recurring income and costs. In particular, JobKeeper income of \$7.61m (FY20: \$7.92m) and acquisition and integration costs of \$4.21m (FY20: \$2.67m) were recorded in FY21.

Reconciliation to Statutory

Reconciliation of Underlying NPATA to Statutory NPAT

| | |
|---|--------------|
| Underlying NPATA attributable to the owners of Healthia Limited (removing impact of AASB16) ¹ | 8,861 |
| Plus: Net income from JobKeeper | 5,614 |
| Less: COVID-19 related expenses | (2,102) |
| Less: Acquisition & integration costs | (4,208) |
| Less: NCI attributed to Jobkeeper | (1,025) |
| Less: Share-based payments expense and associated costs | (1,134) |
| Less: Amortisation | (1,017) |
| Less: Net impact of AASB16 | (588) |
| Less: Bad debt expense | (100) |
| Add: Net taxation impact | 857 |
| Statutory NPAT attributable to the owners of Healthia Limited | 5,157 |

1. Underlying NPATA is a non-IFRS measure and equals net profit after income tax expense plus amortisation of customer list intangibles. Underlying profit reflects statutory profit as adjusted to reflect the Directors' assessment of the result for the ongoing business activities of the consolidated entity, in accordance with AICD/Finsia principles of recording underlying profit. Underlying NPATA has not been audited;

A reconciliation of Underlying NPATA and Statutory NPAT is presented to the right.

Full reconciliation is presented at Table 5 of the Healthia's Annual Financial Report

Further commentary on the adjustments can also be found in the Review of Operations section contained within Healthia's Annual Financial Report

Disclaimer

Except for historical information, there may be matters in this publication that are forward-looking statements. Such statements are only predictions and are subject to inherent risks and uncertainty. Forward-looking statements, which are based on assumptions and estimates and describe the Company's future plans, strategies, and expectations are generally identifiable by the use of the words 'anticipate', 'will', 'believe', 'estimate', 'plan', 'expect', 'intend', 'seek', 'forecast', 'budget' or similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties both general and specific that contribute to the possibility that predictions, forecasts, projections and other forward-looking statements will not occur. Those risks and uncertainties include factors and risks specific to the industry in which the Company operates as well as general economic conditions and prevailing exchange rates and interest rates. Actual performance or events may be materially different from those expressed or implied in those statements.

All forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements in this section.

Except as expressly required by the Act, the Company undertakes no obligation to publicly update or revise any forward-looking statements provided in this publication whether as a result of new information, future events or otherwise, or the risks affecting this information.

None of the Company, its officers or any person named in this publication with their consent, or any person involved in the preparation of this publication, makes any representation or warranty express or implied as to the accuracy or likelihood of fulfilment of any forward-looking statement except to the extent required by law. The forward-looking statements reflect the views held only as at the date of this presentation.

For further information, please contact us

| Company | Company | Investor Relations |
|--|--|---|
| Wesley Coote Group CEO & MD Tel: 07 3180 4900 E: wes.coote@healthia.com.au | Chris Banks CFO & Company Secretary Tel: 07 3180 4900 E: chris.banks@healthia.com.au | Alfred Chan Principal Investor Relations Tel: 03 8080 5780 E: healthia@principalir.com.au |



healthia.com.au
myfootdr.com.au
allsportphysio.com.au
theopticalcompany.com.au



Healthia
Myfootdr
Allsports Physiotherapy
The Optical Company